Table 2.
Characteristics and main findings of the included studies
| First author | Published year | Journal | No of Cases a | Race | Age at onset (years, mean ± SD) |
Height (cm, mean ± SD) |
Weight (kg, mean ± SD) |
BMI (kg/m2, mean ± SD) |
|---|---|---|---|---|---|---|---|---|
| Tuna [3] | 2020 | Gynecol Endocrinol | 9/14 | 31 | 21.3 | |||
| Hardcastle [6] | 2019 | Osteoporos Int | 10 | 1Moroccan, 9NA | 33 | 23.3 | ||
| Scott [23] | 2019 | Osteoporos Int | 1 | Caucasian | 33 | 162 | 74 | 28.2 |
| Ozturk [22] | 2019 | Gynecol Endocrinol | 2 | 33, 28 | 27.4, 22.6 | |||
| Gehlen [11] | 2019 | Clin Rheumatol | 20 | 33.9 | 23.5 | |||
| Zhu [33] | 2018 | Osteoporos Int | 2 | 29 | ||||
| Li [20] | 2018 | Clin Rheumatol | 10/12 | 9Han, 1Manchu | 31 | 21.5 | ||
| Hong [34] | 2018 | Clin Endocrinol | 32 | 31.3 ± 2.6 | 20.3 ± 2.4 | |||
| Butscheidt [35] | 2018 | Osteoporos Int | 5/7 | 35 | 22.8 | |||
| Taraktas [21] | 2018 | Turk J Endocrinol Metab | 1 | 22 | ||||
| Yun [4] | 2017 | Obstet Gynecol Sci | 6 | 32 | 164 | 57 | 21.1 | |
| Kyvernitakis [1] | 2017 | Osteoporos Int | 107 | 39.5 ± 6.0 | 165.9 ± 6.3; | 63.5 ± 11.1 | 23.1 ± 3.7 | |
| Zhang [36] | 2017 | Medicine | 1 | 23 | 21.2 | |||
| Laroche [2] | 2017 | Osteoporos Int | 52 | 27 | ||||
| Ljuin [19] | 2017 | Taiwan J Obstet Gynecol | 1 | 27 | 163 | 45 | 17.1 | |
| Pola [17] | 2016 | J Biol Regul Homeost Agents | 1 | Caucasian | 33 | 167 | 60 | 21.5 |
| Krishnakumar [37] | 2016 | J Craniovert Jun Spine | 2 | 27, 31 | ||||
| Sánchez [18] | 2016 | Clin Cases Miner Bone Metab | 2 | 35, 33 | 162, 157 | |||
| Grana [9] | 2016 | Pain Med | 1 | Caucasian | 31 | |||
| Gaudio [38] | 2016 | Clin Cases Miner Bone Metab | 1 | 38 | 167 | 54 | 19.4 | |
| Ekim [29] | 2016 | J Clin Anal Med | 1 | 35 | 165 | 54 | 19.8 | |
| Polat [39] | 2015 | Gynecol Endocrinol | 1 | 23 | 24.0 | |||
| Hadgaonkar [40] | 2015 | Asian Spine J | 1 | 24 | ||||
| Ozdemir [28] | 2015 | Osteoporos Int | 2 | 34, 36 | 168, 162 | 62, 59 | 21.9, 22.5 | |
| Kovacs [16] | 2015 | Osteoporos Int | 1/2 | 35 | 151 | 46 | 20.0 | |
| Grizzo [26] | 2015 | Calcif Tissue Int | 1 | Caucasian | 31 | 165 | 55 | 20.2 |
| Zarattini [41] | 2014 | Clin Cases Miner Bone Metab | 1 | Caucasian | 27 | 165 | 63 | 23.1 |
| Takahashi [42] | 2014 | Fukushima J Med Sci | 1 | 22 | 163 | 60 | 22.6 | |
| Obando [30] | 2014 | J Clin Endocrinol Metab | 1 | Caucasian | 27 | 158 | 53 | 21.2 |
| Raffaetà [43] | 2014 | Clin Cases Miner Bone Metab | 2 | 42, 21 | 167 | 66 | 23.7 | |
| Ozturk [15] | 2014 | J Obstet Gynaecol | 2 | 22, 34 | ||||
| Baldane [44] | 2014 | Turk Fiz Tip Rehabil Derg | 1 | 35 | 155 | 45 | 18.7 | |
| Winarno [45] | 2014 | Z Geburtsh Neonatol | 1 | 29 | 158 | 46 | 18.4 | |
| Terzi [10] | 2014 | BioMed Res Int | 1 | 32 | ||||
| Cook [46] | 2014 | J Bone Miner Res | 1 | Caucasian | 26 | 161 | 68 | 26.2 |
| Scozzari [47] | 2014 | Acta Medica Mediterranea | 1 | 19 | ||||
| Lee [48] | 2013 | J Bone Metab | 1 | 39 | 156 | 50 | 20.5 | |
| Bonacker [49] | 2013 | Arch Orthop Trauma Surg | 1 | 40 | ||||
| Lwamoto [13] | 2012 | Ther Clin Risk Manag | 1 | 32 | 155 | 57 | 23.7 | |
| Adamidou [50] | 2012 | Horm-Int J Endocrinol Metab | 1 | Caucasian | 40 | 158 | 56 | 22.4 |
| Choe [51] | 2012 | J Bone Miner Metab | 3 | 36, 32, 30 | 20.6, 27.1, 19.4 | |||
| Stupar [52] | 2012 | Rheumatol Int | 1 | 30 | 152 | 52 | 22.5 | |
| Lee [53] | 2011 | J Back Musculoskelet Rehabil | 1 | 31 | 157 | 50 | 20.3 | |
| Mastaglia [25] | 2010 | Osteoporos Int | 1 | 20 | ||||
| Kim [54] | 2010 | J Korean Neurosurg Soc | 1 | 35 | 150 | 42 | 18.7 | |
| Hellmeyer [55] | 2010 | Gynecol Endocrinol | 1 | 40 | 171 | 62 | 21.2 | |
| Tanriover [12] | 2009 | Spine J | 1 | Caucasian | 23 | 169 | 65 | 22.8 |
| Jang [56] | 2009 | Rheumatol Int | 1 | 30 | 163 | 52 | 19.6 | |
| Ofluoglu [57] | 2008 | Rheumatol Int | 1 | 30 | 162 | 50 | 19.1 | |
| Stumpf [27] | 2007 | Adv Med Sci | 2 | 32, 41 | 19.0 | |||
| Hellmeyer [58] | 2007 | Exp Clin Endocrinol Diabet | 1 | 28 | 158 | 46 | 18.4 | |
| O’Sullivan [59] | 2006 | Osteoporos Int | 10 | 9Caucasian, 1Fijian | 31 | 22.0 | ||
| Bayram [60] | 2006 | Joint Bone Spine | 1 | 37 | ||||
| Allali [61] | 2005 | Clin Rheumatol | 1 | 38 | ||||
| Tran [62] | 2002 | Intern Med J | 3 | 2Caucasian, 1NA | 23, 22, 36 | 157, 170, 160 | 47, 48, 47 | 19.1, 16.6, 18.2 |
| Peris [63] | 2002 | Clin Exp Rheumatol | 5 | 31 | 155 | 54 | 22.4 | |
| Yamaga [64] | 2000 | Eur J Obstet Gynecol Reprod Biol | 1 | 25 | ||||
| Gregorio [65] | 2000 | Nutrition | 3 | 3Caucasian | 38, 33, 30 | 155, 151 | 56, 47 | 23.3, 20.5 |
| Anai [66] | 1999 | J Obstet Gynaecol Res | 2 | 24, 30 | 161, 155 | 44, 47 | 17.0, 19.6 | |
| Babbitt [24] | 1998 | J Clin Densitom | 1 | 46 | 175 | 71 | 23.2 | |
| Smith [67] | 1995 | QJM-Mon J Assoc Physicians | 16 | 28 | ||||
| Yamamoto [68] | 1994 | Calcif Tissue Int | 5 | 30 | 153 | 57 | 24.3 | |
| Rillo [69] | 1994 | Clin Rheumatol | 1 | 25 | ||||
| Blanch [70] | 1994 | Br J Rheumatol | 2 | 2Caucasian | 31, 28 | |||
| Reid [71] | 1992 | Clin Endocrinol | 1 | Caucasian | 31 |
NA not available
BMI body mass index
PLO Pregnancy- and lactation-associated osteoporosis
a PLO with vertebral fractures/total population included